Warning Letter Close-Outs – May 2022
Executive Summary
The US FDA released three close-out letters last month, publicly resolving warning letters issued to companies based in Germany, Sweden, and Seattle, WA.
You may also be interested in...
Proposed Rule Would Apply FDA’s Diagnostic Rules To LDTs
A proposed rule from the US Food and Drug Administration would allow the agency to take on regulation of lab-developed tests by phasing out the previous approach of enforcement discretion
OMB Clears Proposed Rule On Lab-Developed Tests
The US FDA appears poised to release long-promised regulations on lab-developed tests. However, some industry observers still have doubts as to whether the agency is truly prepared.
‘The Power Of Persuasion’: FDA Ombudsman Discusses Her Role
During a recent webinar, 20-year FDA chief ombudsman Laurie Lenkel explained why her office sees so many device-related cases and what and ombudsman can, and cannot, do for industry.